db-1311
mAbexperimentalADC
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Sep 5, 2023 (NCT05914116)
Timeline
Indications
Mechanism of action
- CD276 antigenBINDING AGENT
CD276 binding agent
Chemistry & pharmacology
- Payload
- DITAC
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06953089 | Phase 2 | Jul 18, 2025 | Biontech, DualityBio Inc. |
| NCT06892548 | Phase 1/Phase 2 (Phase 2) | May 2, 2025 | Biontech, Biotheus, DualityBio Inc. |
| NCT05914116 | Phase 1/Phase 2 (Phase 2) | Sep 5, 2023 | DualityBio Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| DualityBio Inc. | For profit | 3 | 2 | 1 | 2023 |
| Biontech | For profit | 2 | 1 | 1 | 2025 |
| Biotheus | For profit | 1 | 0 | 1 | 2025 |
3 organizations
Page 1 / 1